Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06452056 · ClinicalTrials.gov registry record
COVID-19 SARS-CoV-2 RAST Study
A clinical trial of SARS-CoV2 Infection, sponsored by Columbia University.
- Completed
- Registry status
- 337
- Enrollment target
- 1
- Study location
NCT06452056 is a study of SARS-CoV2 Infection that has completed, run by Columbia University. The registered enrollment target is 337 participants, below the 1,201-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06452056, a study of SARS-CoV2 Infection, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- 337 participants
- Enrollment target
- 1
- Study location
Study Summary
The SARS-CoV-2 BioMedomics Rapid Antigen Screening Test (COV-SCAN) is an at-home rapid antigen COVID-19 antigen screening test device. The primary objectives of this study are to 1) Evaluate the clinical performance of COV-SCAN; 2.) Assess the usability of COV-SCAN and the paired app as an over-the-counter product to be used by lay persons in non- laboratory settings. The clinical performance and usability data will be submitted as part of an application for Emergency Use Authorization (EUA) to the FDA. 3) Assess acceptability and feasibility of the COV-SCAN test, paired app, and frequent testing regimen in demonstration projects in university and workforce settings.
Conditions Studied
Interventions
- DEVICE Rapid Antigen Screening Test
Study Locations (1)
New York
- Columbia University Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 337 participants |
| Start Date | 2021-01-07 |
| Est. Completion | 2022-12-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06452056
The ClinicalTrials.gov registry entry for NCT06452056 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 337 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,201-participant average among 6 other SARS-CoV2 Infection trials with a reported enrollment target (72% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with SARS-CoV2 Infection appearing as the primary indexed condition, and to 1 intervention - of which Rapid Antigen Screening Test is the first listed.
NCT06452056 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT06452056 about?
NCT06452056 is a clinical study titled "COVID-19 SARS-CoV-2 RAST Study". The SARS-CoV-2 BioMedomics Rapid Antigen Screening Test (COV-SCAN) is an at-home rapid antigen COVID-19 antigen screening test device. The primary objectives of this study are to 1) Evaluate the clinical performance of COV-SCAN; 2.) Assess the usability of COV-SCAN and the paired app as an over-the-...
What is the current status of trial NCT06452056?
This trial is currently completed. The enrollment target is 337 participants. The study started on 2021-01-07. Estimated completion is 2022-12-30.
What conditions does trial NCT06452056 study?
This clinical trial studies the following conditions: SARS-CoV2 Infection.
What interventions are being tested in trial NCT06452056?
The interventions under investigation include: Rapid Antigen Screening Test (DEVICE).
Who is sponsoring clinical trial NCT06452056?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06452056 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for SARS-CoV2 Infection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Outpatient Treatment With Anti-Coronavirus Immunoglobulin
RECRUITING · Phase 3
-
Cellular Senescence and COVID-19 Long-Hauler Syndrome
ACTIVE NOT RECRUITING
-
Pediatric COVID Outcomes Study (PECOS)
ACTIVE NOT RECRUITING
-
Culturally-Targeted COVID-19 Communication and SARS-CoV-2 Antibody Testing Evaluation and Uptake
COMPLETED · NA
-
TekiTrust Tests to Determine the Level of SARS-COV-2/COVID-19 Neutralizing Antibodies in the Blood
COMPLETED
-
A Retrospective Study of COVID-19 Treatments
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.